Kensei Yamaguchi Selected Research

Kensei Yamaguchi Research Topics

Disease

75	Stomach Neoplasms (Stomach Cancer) 07/2022 - 01/2002
71	Neoplasms (Cancer) 08/2022 - 09/2004
71	Colorectal Neoplasms (Colorectal Cancer) 06/2022 - 07/2006
19	Neoplasm Metastasis (Metastasis) 06/2022 - 10/2013
17	Adenocarcinoma 08/2022 - 11/2009
17	Disease Progression 01/2022 - 11/2009
15	Neutropenia 11/2021 - 08/2012
6	Diarrhea 12/2018 - 11/2011
5	Febrile Neutropenia 01/2022 - 01/2006
5	Esophageal Squamous Cell Carcinoma 10/2021 - 01/2017
4	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 02/2014
4	Anemia 01/2020 - 12/2013
4	Microsatellite Instability 04/2019 - 12/2014
4	Colonic Neoplasms (Colon Cancer) 01/2019 - 07/2006
4	Carcinoma (Carcinomatosis) 01/2017 - 08/2006
3	Breast Neoplasms (Breast Cancer) 04/2022 - 11/2018
3	Rectal Neoplasms (Rectal Cancer) 01/2022 - 11/2011
3	Esophageal Neoplasms (Esophageal Cancer) 10/2021 - 05/2020
3	Hypertension (High Blood Pressure) 01/2021 - 03/2018
3	Lymphatic Metastasis 11/2020 - 11/2011
3	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 10/2020 - 03/2009
3	Ascites 01/2020 - 01/2018
3	Anorexia 01/2018 - 10/2013
3	Fatigue 01/2018 - 08/2012
2	Carcinogenesis 06/2022 - 01/2010
2	Residual Neoplasm 03/2020 - 11/2019
2	Hypersensitivity (Allergy) 01/2020 - 01/2002
2	Vomiting 11/2017 - 09/2004

Drug/Important Bio-Agent (IBA)

24	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2022 - 11/2008
22	Cisplatin (Platino)FDA LinkGeneric 08/2022 - 01/2006
20	Fluorouracil (Carac)FDA LinkGeneric 05/2022 - 11/2009
20	Irinotecan (Camptosar)FDA LinkGeneric 04/2020 - 01/2007
15	Cetuximab (Erbitux)FDA Link 06/2022 - 11/2008
15	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2014
14	Trastuzumab (Herceptin)FDA Link 04/2022 - 07/2012
13	Leucovorin (Folinic Acid)FDA Link 11/2021 - 09/2010
12	NivolumabIBA 07/2022 - 01/2017
12	RamucirumabIBA 07/2022 - 07/2016
12	Capecitabine (Xeloda)FDA Link 01/2022 - 07/2006
12	Bevacizumab (Avastin)FDA Link 01/2022 - 10/2010
12	Paclitaxel (Taxol)FDA LinkGeneric 11/2021 - 01/2002
11	S-1 plus cisplatinIBA 01/2022 - 07/2012
10	ErbB Receptors (EGF Receptor)IBA 06/2022 - 08/2013
10	PlatinumIBA 05/2022 - 08/2013
9	trifluridine tipiracil drug combinationIBA 11/2021 - 10/2012
8	regorafenibIBA 10/2021 - 06/2016
7	Monoclonal AntibodiesIBA 01/2022 - 10/2017
7	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2010
6	human ERBB2 proteinIBA 08/2022 - 08/2017
6	Circulating Tumor DNAIBA 12/2021 - 01/2019
6	Pharmaceutical PreparationsIBA 03/2020 - 08/2012
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 06/2016
4	pembrolizumabIBA 08/2022 - 01/2017
4	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2019
4	trastuzumab deruxtecanIBA 01/2021 - 01/2019
4	CreatinineIBA 01/2019 - 07/2016
4	XELOXIBA 05/2018 - 10/2010
4	ChemokinesIBA 06/2016 - 07/2008
4	NucleolinIBA 05/2014 - 01/2010
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2010 - 01/2006
3	B7-H1 AntigenIBA 08/2022 - 01/2021
3	Tumor Biomarkers (Tumor Markers)IBA 12/2021 - 11/2018
3	Panitumumab (Vectibix)FDA Link 07/2021 - 06/2016
3	LigandsIBA 01/2021 - 06/2016
3	Therapeutic UsesIBA 01/2021 - 11/2017
3	Epidermal Growth Factor (EGF)IBA 01/2021 - 07/2012
3	NF-kappa B (NF-kB)IBA 06/2010 - 01/2006
2	C-Reactive ProteinIBA 04/2022 - 01/2022
2	andecaliximabIBA 01/2022 - 01/2022
2	EnzymesIBA 01/2022 - 09/2004
2	IpilimumabIBA 01/2022 - 10/2017
2	Carcinoembryonic AntigenIBA 12/2021 - 11/2018
2	afliberceptIBA 01/2021 - 08/2013
2	CarbohydratesIBA 11/2020 - 11/2018
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2020 - 05/2014
2	HLA Antigens (Human Leukocyte Antigens)IBA 05/2020 - 04/2020
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2020 - 01/2006
2	taxaneIBA 02/2020 - 01/2017
2	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 11/2013
2	AntibodiesIBA 01/2019 - 11/2017
2	Leucine (L-Leucine)FDA Link 11/2018 - 01/2007
2	Codon (Codons)IBA 09/2013 - 01/2007

Therapy/Procedure

79	Drug Therapy (Chemotherapy) 08/2022 - 01/2002
46	Therapeutics 01/2022 - 01/2002
9	Adjuvant Chemotherapy 01/2022 - 07/2006
7	Combination Drug Therapy (Combination Chemotherapy) 05/2022 - 07/2007
5	Gastrectomy 12/2021 - 11/2018
4	Chemoradiotherapy 01/2022 - 11/2011
4	Neoadjuvant Therapy 01/2022 - 06/2019
3	Immunotherapy 01/2021 - 04/2020
2	Aftercare (After-Treatment) 01/2022 - 11/2019
2	Intravenous Infusions 01/2022 - 08/2012
2	Precision Medicine 01/2022 - 11/2021
2	Hepatectomy 11/2020 - 11/2013
2	Treatment Delay 01/2020 - 11/2011
2	Molecular Targeted Therapy 02/2017 - 04/2011
2	Salvage Therapy 06/2016 - 06/2016
2	Oral Administration 02/2014 - 11/2009
2	Drug Tapering 02/2014 - 11/2011
2	Premedication 08/2012 - 01/2002